Jefferies cuts Collegium Pharmaceutical stock price target on pain business concerns
Jefferies reduced its price target for Collegium Pharmaceutical (COLL) to $35 from $51, citing concerns about its pain business. The stock is down 45.66% year-to-date. The company reported Q3 2026 earnings, beating EPS estimates but meeting revenue expectations. Management plans to continue share buybacks and deleverage. Jefferies expects modest EBITDA growth by 2027, with ADHD business growth offsetting pain segment declines.
How this was made
The 30-second read
Why it matters
The earnings beat provides limited upside, but the target reduction signals valuation concerns, likely keeping the stock under pressure.
Market read
The article delivers fresh earnings data and a new analyst price target, offering a medium‑term trading signal for COLL.
What to watch
Strong ADHD growth could offset pain segment weakness if sustained.
Background
Collegium Pharmaceutical reported Q3 2026 results with EPS beat and reaffirmed guidance, while Jefferies cut its price target due to concerns over the opioid pain business.
Ticker impact
Jefferies lowered its price target on Collegium Pharmaceutical to $35 from $51 and reported the company's Q3 2026 earnings beat on EPS.
likely pressure as the market prices in the lower target and weak pain business outlook
Analyst downgrade on valuation combined with modest earnings growth signals limited upside.
Market effects
Pain management segment may face continued scrutiny, affecting peers in the opioid space.
U.S. biotech sector sees modest impact from the target cut.
Limited to investors tracking small-cap pharma stocks.
Counterpoint
Buy rating remains unchanged; the lower target may present a buying opportunity at current levels.
Key entities
- CompanyCollegium Pharmaceutical
U.S.-listed pharmaceutical company focusing on ADHD and pain management.
- Research FirmJefferies
Equity research analyst firm that issued the price target cut.



